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Abstract
About 40% of patients treated with antidepressant do not show a response. However, the underlying mechanisms remain unclear and there is no objective test for the prediction of treatment response. The aim of this study was to investigate the proteomic differences between responder and non-responder in patients with major depressive disorder (MDD who were treated with escitalopram. Fasting blood samples were collected and Clinical Global Impression scale (CGI) was completed at baseline and at day 3, 7, 12, and 42. Five patients who completed the 42days study treatment were included in proteomic analysis. We performed liquid chromatography-mass spectrometry (LC-MS) based proteomics for quantitative profiling of the serum proteomes from seven patients with MDD. Data-independent acquisition (DIA) method was employed for the quantification of each serum proteome. In order to identify proteins that are correlated throughout the antidepressant treatment, the Pearson's correlation coefficients between the protein profiles were calculated and the expression correlation networks (ExprsCorrNetwork) were constructed. The escitalopram network was constructed to identify functional associations between the serum proteins and the drug response. The genes associated with escitaloprm were retrieved from PharmGKB database and the 1st interactors of the seed genes were parsed from the protein-protein interaction network of BioGrid. Then, the overlaps between the ExprsCorrNetwork and the escitalopram 
Depression and anxiety disorders are two of the most common mental illnesses. It is pathognomonic that patients with depressive symptoms show frontal EEG alpha asymmetry while asymmetries related to other EEG wave frequencies have not been consistently reported. The purpose of the study was to examine whether patients who have depression and anxiety disorders together have significant, distinctive characteristics in their EEG activities using qEEG. Twenty-one electrodes of Geodesic 64 channel qEEG device was utilized to measure two groups of participants for five minutes: seven patients with both depression and anxiety disorders (3 males, 4 females, mean age 49.7) in resting state (Eyes closed) and eight normal controls (6 males, 1 female, mean age 24.7). The data were analyzed with NeuroGuide ver. 2.8.5 and were statistically analyzed with the Mann Whitney U-test to compare asymmetries of the two elctrodes. The results suggested that theta waves were significantly active at Fp1-Fp2 (p > 0.002), Fp1-C3 (p > 0.001), Fp2-C3 (p > 0.001), Fp2-P3 (p > 0.004), and Fz-C3 (p > 0.002). The preliminary findings demonstrate that frontal and central EEG theta asymmetries may be associated with patient who report both depressive and anxious symptoms. This, in turn, indicates that qEEG can become useful when it is assessed and analyzed objectively and also provide psychiatrists with opportunities to conduct various assessments. The present research will be developed with additional data.
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